BioSpace News Archive

Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the acceptance of its Clinical Trial Application (CTA) from the National Agency for the Safety of Medicines and Health Products (ANSM) in France to allow initiation of its Phase 1/2 clinical trial of INZ-701,

KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced its expected addition to the broad-market Russell 3000® Index and the Russell 2000® Index in accordance with the 2021 Russell indexes annual reconstitution.

Mind Medicine announces that J.R. Rahn, the Company’s co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Jennifer Good, President and CEO, has b